Innate Pharma Announces Advancement of Sanofi-Developed NK Cell Engager SAR443579/IPH6101 Progressing to Phase II for Blood Cancer Patients

Innate Pharma SA announced that the first patient was dosed in the Phase II dose expansion part of the Sanofi-sponsored clinical trial of SAR443579 / IPH6101, evaluating SAR443579 as a monotherapy for the treatment of blood cancers with high unmet needs.